Sponsors & Exhibitors
Commercial opportunities
Choose from a variety of sponsorship and commercial options to raise your profile and position your company as a thought leader in the community.
Reasons why being a sponsor is a brilliant marketing strategy
Highly targeted marketing – reach your community
Brand awareness & recognition – logo and advertisement placement
Access to knowledge – find out about new research being undertaken
Engage with your audience online
Media exposure - benefit from being promoted throughout Elsevier’s marketing process
Enhance credibility – highlight your company’s expertise to a captive audience
Generate new sales & form new partnerships – with registrants, vendors and speakers
Leveraged lead generation - the chance to be recommended to attendees’ connections
To discuss your requirements or to book sponsorship or exhibit space please contact:
Chloe Partridge Conference Sponsorship & Classified Advertising Sales Executive Tel: +44 (0) 1865 843 346 Email: [email protected] 새 탭/창에서 열기
Please do not email credit card information under any circumstances
Shionogi
Shionogi's policy is to "supply the best possible medicine to protect the health and wellbeing of the patients we serve." Our mission, based on this policy, as a research-driven pharmaceutical company, is to deliver pharmaceuticals that offer the greatest possible level of satisfaction to patients, their families, and healthcare providers and that improve quality of life (QOL) for patients and their families worldwide. To achieve this goal, we are constantly engaged in research, development, manufacturing, and marketing activities, with a primary focus on prescription medicines, including vaccines, as well as OTC drugs and diagnostics.
Exhibitor
EVORA
EVORA will contribute to strengthening the competitiveness of the European Research Area (ERA) by providing operational state-of-the-art facilities, supporting European industry in the field of communicable diseases and to providing recommendations for harmonised policies and regulations. Establishing an operational RI alliance that offers a range of tailored, integrated resources and preclinical research services for studying viral pathogens with epidemic or pandemic potential, will be the demonstration of EVORA’s success.
